
    
      This is a single arm, phase two study. Eligible patients with advanced MSI-H/dMMR colorectal
      cancer were assigned to receive BAT1306 plus COX inhibitor. All patients will receive the
      study regimen every 3 weeks. Chest/abdomen/pelvic CT with IV contrast will be performed to
      assess clinical response.
    
  